Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
JCI Insight ; 3(9)2018 05 03.
Article in English | MEDLINE | ID: mdl-29720578

ABSTRACT

Sepsis-associated encephalopathy manifesting as delirium is a common problem in critical care medicine. In this study, patients that had delirium due to sepsis had significant cognitive impairments at 12-18 months after hospital discharge when compared with controls and Cambridge Neuropsychological Automated Test Battery-standardized scores in spatial recognition memory, pattern recognition memory, and delayed-matching-to-sample tests but not other cognitive functions. A mouse model of S. pneumoniae pneumonia-induced sepsis, which modeled numerous aspects of the human sepsis-associated multiorgan dysfunction, including encephalopathy, also revealed similar deficits in spatial memory but not new task learning. Both humans and mice had large increases in chemokines for myeloid cell recruitment. Intravital imaging of the brains of septic mice revealed increased neutrophil and CCR2+ inflammatory monocyte recruitment (the latter being far more robust), accompanied by subtle microglial activation. Prevention of CCR2+ inflammatory monocyte recruitment, but not neutrophil recruitment, reduced microglial activation and other signs of neuroinflammation and prevented all signs of cognitive impairment after infection. Therefore, therapeutically targeting CCR2+ inflammatory monocytes at the time of sepsis may provide a novel neuroprotective clinical intervention to prevent the development of persistent cognitive impairments.


Subject(s)
Brain/pathology , Cognitive Dysfunction/pathology , Cytokines/blood , Inflammation/blood , Monocytes/pathology , Sepsis-Associated Encephalopathy/pathology , Adult , Aged , Animals , Antibodies, Monoclonal/therapeutic use , Cognitive Dysfunction/microbiology , Disease Models, Animal , Female , Humans , Inflammation/microbiology , Interleukin-8/antagonists & inhibitors , Interleukin-8/immunology , Intravital Microscopy , Male , Mental Status and Dementia Tests , Mice , Microglia/physiology , Middle Aged , Monocytes/metabolism , Neutrophils/pathology , Pneumococcal Infections/complications , Receptors, CCR2/antagonists & inhibitors , Receptors, CCR2/immunology , Receptors, CCR2/metabolism , Sepsis-Associated Encephalopathy/blood , Sepsis-Associated Encephalopathy/microbiology
2.
PLoS One ; 8(2): e57390, 2013.
Article in English | MEDLINE | ID: mdl-23437381

ABSTRACT

This study investigated how both sex and individual differences in a mental rotation test (MRT) influence performance on working memory (WM). To identify the neural substrate supporting these differences, brain electrical activity was measured using the event-related potential technique. No significant sex differences were observed in a test of verbal WM, however males were significantly faster than females to respond to probe stimuli in a test of spatial WM. This difference was no longer significant after controlling for differences in MRT score, suggesting that rotational ability mediates performance in the spatial memory task for both sexes. A posterior P300 was observed in both tasks as participants encoded information into memory, however the amplitude of the P300 correlated with RT in the spatial task but not in the verbal task. Individual differences in the MRT also correlated with RT and with the amplitude of the P300, but again only in the spatial task. After splitting the analysis by sex, partial correlations controlling for MRT revealed that for males, individual differences in rotational ability completely mediated the correlation between the P300 and RT in the spatial task. This mediating effect was not observed for the female participants. The results therefore suggest a relatively stronger association in males between innate mental rotational ability, spatial memory performance, and brain electrophysiological processes supporting spatial memory.


Subject(s)
Event-Related Potentials, P300/physiology , Memory, Short-Term/physiology , Space Perception/physiology , Verbal Learning/physiology , Adolescent , Adult , Electroencephalography , Female , Humans , Individuality , Intelligence Tests , Male , Neuropsychological Tests , Reaction Time/physiology , Research Design , Rotation , Sex Factors
3.
PLoS One ; 7(4): e35417, 2012.
Article in English | MEDLINE | ID: mdl-22514741

ABSTRACT

A number of antiepileptic medications that modulate GABA(A) mediated synaptic transmission are anxiolytic. The loop diuretics furosemide (Lasix) and bumetanide (Bumex) are thought to have antiepileptic properties. These drugs also modulate GABA(A) mediated signalling through their antagonism of cation-chloride cotransporters. Given that loop diuretics may act as antiepileptic drugs that modulate GABAergic signalling, we sought to investigate whether they also mediate anxiolytic effects. Here we report the first investigation of the anxiolytic effects of these drugs in rat models of anxiety. Furosemide and bumetanide were tested in adult rats for their anxiolytic effects using four standard anxiety models: 1) contextual fear conditioning; 2) fear-potentiated startle; 3) elevated plus maze, and 4) open-field test. Furosemide and bumetanide significantly reduced conditioned anxiety in the contextual fear-conditioning and fear-potentiated startle models. At the tested doses, neither compound had significant anxiolytic effects on unconditioned anxiety in the elevated plus maze and open-field test models. These observations suggest that loop diuretics elicit significant anxiolytic effects in rat models of conditioned anxiety. Since loop diuretics are antagonists of the NKCC1 and KCC2 cotransporters, these results implicate the cation-chloride cotransport system as possible molecular mechanism involved in anxiety, and as novel pharmacological target for the development of anxiolytics. In view of these findings, and since furosemide and bumetanide are safe and well tolerated drugs, the clinical potential of loop diuretics for treating some types of anxiety disorders deserves further investigation.


Subject(s)
Anti-Anxiety Agents/adverse effects , Anti-Anxiety Agents/therapeutic use , Anxiety/drug therapy , Sodium Potassium Chloride Symporter Inhibitors/therapeutic use , Animals , Bumetanide/adverse effects , Bumetanide/therapeutic use , Disease Models, Animal , Furosemide/adverse effects , Furosemide/therapeutic use , Male , Rats , Rats, Long-Evans , Sodium Potassium Chloride Symporter Inhibitors/adverse effects
SELECTION OF CITATIONS
SEARCH DETAIL
...